Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study

Respiratory Medicine

Volumn 132, Issue , 2017, Pages 31-41

  Ferguson, Gary T ^a   Tashkin, Donald P ^b   Skärby, Tor ^c   Jorup, Carin ^c   Sandin, Kristina ^c   Greenwood, Michael ^d,e   Pemberton, Kristine ^d   Trudo, Frank ^d  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e PHASTAR   (United Kingdom)

Author keywords

Airway; Budesonide formoterol; COPD; ICS LABA; Lung

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CARDIOPULMONARY INSUFFICIENCY; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CONTUSION; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRY POWDER INHALER; DYSPHONIA; FEMALE; FIBULA FRACTURE; FOOT FRACTURE; HAND FRACTURE; HEART ARREST; HEART INFARCTION; HUMAN; INSOMNIA; INTRAOCULAR PRESSURE; LIMB FRACTURE; LOWER LIMB FRACTURE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; OSTEOPOROSIS; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RHINOPHARYNGITIS; RIB FRACTURE; RISK REDUCTION; SENSITIVITY ANALYSIS; SIDE EFFECT; SPINE FRACTURE; THORACIC VERTEBRAL FRACTURE; THRUSH; TIBIA FRACTURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER LIMB FRACTURE; COMPARATIVE STUDY; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85029886323     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.09.002     Document Type: Article

References (21)

1. Cote, C.G., Dordelly, L.J., Celli, B.R., Impact of COPD exacerbations on patient-centered outcomes. Chest 131:3 (2007), 696–704.
2. Halpin, D.M., Decramer, M., Celli, B., Kesten, S., Liu, D., Tashkin, D.P., Exacerbation frequency and course of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 7 (2012), 653–661.
3. Beeh, K.M., Glaab, T., Stowasser, S., et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir. Res., 14, 2013, 116.
4. Soler-Cataluña, J.J., Martínez-García, M.A., Román Sánchez, P., Salcedo, E., Navarro, M., Ochando, R., Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:11 (2005), 925–931.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Report 2017. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed 16 November, 2016.
6. Hurst, J.R., Vestbo, J., Anzueto, A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363:12 (2010), 1128–1138.
7. Martinez, F.J., Han, M.K., Flaherty, K., Curtis, J., Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev. Anti Infect. Ther. 4:1 (2006), 101–124.
8. Anzueto, A., Ferguson, G.T., Feldman, G., et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 6:5 (2009), 320–329.
9. Calverley, P.M., Anderson, J.A., Celli, B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356:8 (2007), 775–789.
10. Ferguson, G.T., Anzueto, A., Fei, R., Emmett, A., Knobil, K., Kalberg, C., Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir. Med. 102:8 (2008), 1099–1108.
11. Jenkins, C.R., Jones, P.W., Calverley, P.M., et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res., 10, 2009, 59.
12. Rennard, S.I., Tashkin, D.P., McElhattan, J., et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69:5 (2009), 549–565.
13. Sharafkhaneh, A., Southard, J.G., Goldman, M., Uryniak, T., Martin, U.J., Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir. Med. 106:2 (2012), 257–268.
14. Tashkin, D.P., Rennard, S.I., Martin, P., et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 68:14 (2008), 1975–2000.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry; Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment.., November 2016 http://qibawiki.rsna.org/images/4/41/FDA-COPDGuidance-20100201.pdf. (Accessed 18 November 2016)
16. Anthonisen, N.R., Manfreda, J., Warren, C.P., Hershfield, E.S., Harding, G.K., Nelson, N.A., Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern Med. 106:2 (1987), 196–204.
17. Al-ani, S., Spigt, M., Hofset, P., Melbye, H., Predictors of exacerbations of asthma and COPD during one year in primary care. Fam. Pract. 30:6 (2013), 621–628.
18. Husebø, G.R., Bakke, P.S., Aanerud, M., et al. Predictors of exacerbations in chronic obstructive pulmonary disease–results from the Bergen COPD cohort study. PLoS One, 9(10), 2014, e109721.
19. Sin, D.D., McAlister, F.A., Man, S.F., Anthonisen, N.R., Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290:17 (2003), 2301–2312.
20. Sin, D.D., Tashkin, D., Zhang, X., et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 374:9691 (2009), 712–719.
21. Hollis, S., Jorup, C., Lythgoe, D., et al. Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies. Int. J. Chron. Obstruct. Pulmon. Dis. 12 (2017), 1071–1084.